Logo image of MDNA

MEDICENNA THERAPEUTICS CORP (MDNA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MDNA - CA58490H1073 - Common Stock

0.157 USD
-0.02 (-13.16%)
Last: 11/1/2023, 8:00:01 PM
0.1565 USD
0 (-0.32%)
After Hours: 11/1/2023, 8:00:01 PM
Fundamental Rating

3

Overall MDNA gets a fundamental rating of 3 out of 10. We evaluated MDNA against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MDNA as it has an excellent financial health rating, but there are worries on the profitability. MDNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDNA has reported negative net income.
MDNA had a negative operating cash flow in the past year.
MDNA had negative earnings in each of the past 5 years.
MDNA had a negative operating cash flow in each of the past 5 years.
MDNA Yearly Net Income VS EBIT VS OCF VS FCFMDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

MDNA has a better Return On Assets (-27.75%) than 73.60% of its industry peers.
MDNA has a Return On Equity of -32.55%. This is in the better half of the industry: MDNA outperforms 79.04% of its industry peers.
Industry RankSector Rank
ROA -27.75%
ROE -32.55%
ROIC N/A
ROA(3y)-54.92%
ROA(5y)-55.46%
ROE(3y)-62.59%
ROE(5y)-78.09%
ROIC(3y)N/A
ROIC(5y)N/A
MDNA Yearly ROA, ROE, ROICMDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDNA Yearly Profit, Operating, Gross MarginsMDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, MDNA has more shares outstanding
The number of shares outstanding for MDNA has been increased compared to 5 years ago.
MDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDNA Yearly Shares OutstandingMDNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
MDNA Yearly Total Debt VS Total AssetsMDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

MDNA has an Altman-Z score of -2.42. This is a bad value and indicates that MDNA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.42, MDNA is in line with its industry, outperforming 48.84% of the companies in the same industry.
MDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.42
ROIC/WACCN/A
WACCN/A
MDNA Yearly LT Debt VS Equity VS FCFMDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 9.74 indicates that MDNA has no problem at all paying its short term obligations.
MDNA's Current ratio of 9.74 is fine compared to the rest of the industry. MDNA outperforms 72.44% of its industry peers.
MDNA has a Quick Ratio of 9.74. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
MDNA has a better Quick ratio (9.74) than 72.61% of its industry peers.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.74
MDNA Yearly Current Assets VS Current LiabilitesMDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.76% over the past year.
EPS 1Y (TTM)56.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MDNA will show a very strong growth in Earnings Per Share. The EPS will grow by 51.29% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.16%
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%
EPS Next 5Y51.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDNA Yearly Revenue VS EstimatesMDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
MDNA Yearly EPS VS EstimatesMDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDNA Price Earnings VS Forward Price EarningsMDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDNA Per share dataMDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

A cheap valuation may be justified as MDNA's earnings are expected to decrease with -17.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICENNA THERAPEUTICS CORP

NASDAQ:MDNA (11/1/2023, 8:00:01 PM)

After market: 0.1565 0 (-0.32%)

0.157

-0.02 (-13.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2023-07-28/bmo
Earnings (Next)11-09 2023-11-09/bmo
Inst Owners0.18%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.93M
Revenue(TTM)N/A
Net Income(TTM)-8.76M
Analysts83.64
Price Target2.88 (1734.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.91%
Min EPS beat(2)29.41%
Max EPS beat(2)36.41%
EPS beat(4)4
Avg EPS beat(4)46.58%
Min EPS beat(4)29.41%
Max EPS beat(4)78.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.64%
PT rev (3m)-18.64%
EPS NQ rev (1m)1%
EPS NQ rev (3m)5.71%
EPS NY rev (1m)0%
EPS NY rev (3m)3.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.75%
ROE -32.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.92%
ROA(5y)-55.46%
ROE(3y)-62.59%
ROE(5y)-78.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.74
Altman-Z -2.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y-26.16%
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%
EPS Next 5Y51.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.59%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICENNA THERAPEUTICS CORP / MDNA FAQ

Can you provide the ChartMill fundamental rating for MEDICENNA THERAPEUTICS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to MDNA.


What is the valuation status for MDNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICENNA THERAPEUTICS CORP (MDNA). This can be considered as Overvalued.


What is the profitability of MDNA stock?

MEDICENNA THERAPEUTICS CORP (MDNA) has a profitability rating of 1 / 10.